Vigil NeuroscienceVIGL
About: Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Employees: 64
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
15% more capital invested
Capital invested by funds: $90.6M [Q1] → $105M (+$13.9M) [Q2]
6% more funds holding
Funds holding: 54 [Q1] → 57 (+3) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
2.42% less ownership
Funds ownership: 71.95% [Q1] → 69.53% (-2.42%) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Guggenheim Yatin Suneja 65% 1-year accuracy 13 / 20 met price target | 371%upside $16 | Buy Maintained | 14 Aug 2024 |
HC Wainwright & Co. Andrew Fein 43% 1-year accuracy 74 / 172 met price target | 400%upside $17 | Buy Reiterated | 14 Aug 2024 |
HC Wainwright & Co. Andrew Fein 43% 1-year accuracy 74 / 172 met price target | 400%upside $17 | Buy Reiterated | 25 Jul 2024 |
HC Wainwright & Co. Andrew Fein 43% 1-year accuracy 74 / 172 met price target | 400%upside $17 | Buy Maintained | 19 Jul 2024 |
Wedbush Laura Chico 52% 1-year accuracy 38 / 73 met price target | 576%upside $23 | Outperform Reiterated | 11 Jul 2024 |